News & Events

August 1, 2018

Alkahest, Inc. Announces Key Appointment

Bruce Morimoto joins Alkahest as Vice President, Drug Development Operations

SAN CARLOS, Calif.,  — Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing new treatments for neurodegenerative diseases and other age-related conditions, announced today the... Continue Reading

July 23, 2018

Alkahest to Present at Alzheimer’s Association International Conference (AAIC) Annual Meeting July 22-26, 2018 Chicago, IL

Presentations highlight a novel multifactorial approach to the treatment of Alzheimer's Disease

SAN CARLOS, Calif.,  — Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat Alzheimer's Disease and other age-related diseases,... Continue Reading

June 18, 2018

Alkahest, Inc. Announces Key Appointment

Michael Byrnes joins Alkahest as Chief Financial Officer

SAN CARLOS, Calif.,  — Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing new treatments for neurodegenerative diseases and other age-related conditions, announced today the appointment of... Continue Reading

May 21, 2018

Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support Preclinical Evaluation of ALK4290 for Parkinson’s Disease

SAN CARLOS, Calif., — Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) entitled... Continue Reading

May 14, 2018

Alkahest Announces Initiation of Two Phase 2 Clinical Trials of ALK4290 in Age-Related Macular Degeneration

SAN CARLOS, Calif.,  — Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced the initiation of two Phase 2 clinical trials of ALK4290 in patients with the wet form of age-related macular... Continue Reading

April 25, 2018

Alkahest Announces Initiation of Phase 2 Clinical Trial of GRF6019 in Alzheimer’s Disease

First patient dosed with plasma-derived product GRF6019

SAN CARLOS, Calif.,  — Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced the initiation of a Phase 2 randomized, double-blinded... Continue Reading

February 12, 2018

Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support the Clinical Development of a Novel Parkinson’s Therapy

SAN CARLOS, Calif. — Alkahest Inc., a privately held, clinical stage biopharmaceutical company focused on neurodegenerative and other age-related diseases, announced today that is has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support a... Continue Reading

January 23, 2018

Alkahest, Inc. Announces Key Appointments

SAN CARLOS, Calif. — Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing new treatments for neurodegenerative diseases and other age-related conditions, announced today the appointments of Karl G. Trass as Vice President, Regulatory Affairs and Jonas... Continue Reading

November 10, 2017

Alkahest to Present at Society for Neuroscience 47th Annual Meeting

SAN CARLOS, Calif. — Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced upcoming presentations at the Society for Neuroscience 47th Annual Meeting, taking place November 11-15, 2017 in... Continue Reading

November 1, 2017

Alkahest to Present Clinical Results from PLASMA Study in Patients with Mild to Moderate Alzheimer’s Disease at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

SAN CARLOS, Calif. — Alkahest, Inc. (“Alkahest”), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced an upcoming oral presentation at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) conference. The... Continue Reading